PRR5
Basic information
Region (hg38): 22:44668547-44737681
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the PRR5 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 23 | 25 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 0 | 23 | 2 | 0 |
Variants in PRR5
This is a list of pathogenic ClinVar variants found in the PRR5 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
22-44679839-T-C | not specified | Uncertain significance (Sep 20, 2023) | ||
22-44679840-C-T | not specified | Uncertain significance (Oct 22, 2021) | ||
22-44679859-G-A | not specified | Uncertain significance (Dec 01, 2022) | ||
22-44679864-C-T | not specified | Uncertain significance (Mar 20, 2024) | ||
22-44679875-G-T | not specified | Uncertain significance (Jan 03, 2024) | ||
22-44702496-A-C | not specified | Uncertain significance (Aug 20, 2024) | ||
22-44702535-A-G | not specified | Uncertain significance (Jan 19, 2024) | ||
22-44714622-C-A | not provided (-) | |||
22-44726633-G-T | not specified | Uncertain significance (Dec 06, 2021) | ||
22-44731747-T-G | not specified | Uncertain significance (Oct 11, 2024) | ||
22-44731768-T-G | not specified | Uncertain significance (Sep 14, 2022) | ||
22-44731769-T-A | not specified | Uncertain significance (Sep 14, 2022) | ||
22-44731774-T-C | not specified | Uncertain significance (May 10, 2024) | ||
22-44731792-A-G | not specified | Uncertain significance (Apr 23, 2024) | ||
22-44731807-T-C | not specified | Uncertain significance (Apr 29, 2024) | ||
22-44732278-G-A | not specified | Uncertain significance (Jan 23, 2024) | ||
22-44732311-A-G | not specified | Uncertain significance (Jun 21, 2021) | ||
22-44732312-G-A | not specified | Uncertain significance (Feb 16, 2023) | ||
22-44732330-C-T | not specified | Uncertain significance (Dec 13, 2021) | ||
22-44732338-C-T | not specified | Uncertain significance (Aug 28, 2024) | ||
22-44732339-G-A | not specified | Uncertain significance (Sep 29, 2022) | ||
22-44732350-C-T | not specified | Uncertain significance (Apr 06, 2024) | ||
22-44732359-C-G | not specified | Uncertain significance (Feb 27, 2024) | ||
22-44732384-T-C | not specified | Uncertain significance (Dec 13, 2023) | ||
22-44735048-G-A | not specified | Uncertain significance (Jan 20, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
PRR5 | protein_coding | protein_coding | ENST00000403581 | 9 | 68969 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0669 | 0.930 | 125693 | 0 | 37 | 125730 | 0.000147 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.240 | 276 | 265 | 1.04 | 0.0000184 | 2596 |
Missense in Polyphen | 91 | 94.502 | 0.96295 | 1000 | ||
Synonymous | -0.406 | 131 | 125 | 1.05 | 0.00000916 | 866 |
Loss of Function | 2.63 | 5 | 16.6 | 0.302 | 7.06e-7 | 197 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000242 | 0.000242 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000445 | 0.000435 |
Finnish | 0.000100 | 0.0000924 |
European (Non-Finnish) | 0.000127 | 0.000123 |
Middle Eastern | 0.000445 | 0.000435 |
South Asian | 0.000212 | 0.000196 |
Other | 0.000169 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Subunit of mTORC2, which regulates cell growth and survival in response to hormonal signals. mTORC2 is activated by growth factors, but, in contrast to mTORC1, seems to be nutrient- insensitive. mTORC2 seems to function upstream of Rho GTPases to regulate the actin cytoskeleton, probably by activating one or more Rho-type guanine nucleotide exchange factors. mTORC2 promotes the serum-induced formation of stress-fibers or F-actin. mTORC2 plays a critical role in AKT1 'Ser-473' phosphorylation, which may facilitate the phosphorylation of the activation loop of AKT1 on 'Thr-308' by PDK1 which is a prerequisite for full activation. mTORC2 regulates the phosphorylation of SGK1 at 'Ser-422'. mTORC2 also modulates the phosphorylation of PRKCA on 'Ser-657'. PRR5 plays an important role in regulation of PDGFRB expression and in modulation of platelet-derived growth factor signaling. May act as a tumor suppressor in breast cancer. {ECO:0000269|PubMed:15718101, ECO:0000269|PubMed:17599906}.;
- Pathway
- mTOR signaling pathway - Homo sapiens (human);Target Of Rapamycin (TOR) Signaling;Disease;Signal Transduction;Gene expression (Transcription);VEGFA-VEGFR2 Pathway;Generic Transcription Pathway;CD28 dependent PI3K/Akt signaling;CD28 co-stimulation;Costimulation by the CD28 family;RNA Polymerase II Transcription;Immune System;Adaptive Immune System;Regulation of TP53 Degradation;Regulation of TP53 Expression and Degradation;PIP3 activates AKT signaling;Regulation of TP53 Activity;Transcriptional Regulation by TP53;Signaling by VEGF;Constitutive Signaling by AKT1 E17K in Cancer;PI3K/AKT Signaling in Cancer;Signaling by Receptor Tyrosine Kinases;Intracellular signaling by second messengers;mTOR signaling pathway;Diseases of signal transduction;VEGFR2 mediated vascular permeability
(Consensus)
Recessive Scores
- pRec
- 0.139
Intolerance Scores
- loftool
- 0.655
- rvis_EVS
- 0.44
- rvis_percentile_EVS
- 77.91
Haploinsufficiency Scores
- pHI
- hipred
- Y
- hipred_score
- 0.640
- ghis
- 0.460
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.895
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Prr5
- Phenotype
Gene ontology
- Biological process
- cell cycle;positive regulation of phosphatidylinositol 3-kinase signaling;activation of protein kinase B activity;TORC2 signaling
- Cellular component
- cytosol;TORC2 complex
- Molecular function
- protein binding